Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915417 | 0.89 | POLB (0.52) | POLBAKR1B1MAPTL3MBTL1KMT2A | |
| SCHEMBL23909094 | 0.76 | MAPT (0.64) | POLBAKR1B1MAPTL3MBTL1KMT2A | |
| SCHEMBL9218773 | 0.73 | POLB (0.69) | POLBAKR1B1MAPTKMT2A | |
| SCHEMBL23908905 | 0.72 | MAPT (0.67) | POLBMAPTL3MBTL1KMT2AKDM4E | |
| SCHEMBL15597471 | 0.71 | MAPT (0.68) | POLBMAPTL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL23914926 | 0.71 | MAPT (0.48) | POLBAKR1B1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL23914636 | 0.70 | SMN1; SMN2 (0.50) | POLBMAPTKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL23915521 | 0.69 | MAPT (0.69) | POLBAKR1B1MAPTKMT2APTGDR2 | |
| SCHEMBL6890822 | 0.69 | MAPT (1.00) | POLBAKR1B1MAPTKMT2ARECQL | |
| SCHEMBL23909111 | 0.69 | MAPT (0.73) | POLBMAPTL3MBTL1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | POLB 3606/4885AKR1B1 124/4885MAPT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.